A Study to Evaluate the Food Effect on the Pharmacokinetics of NVP-1203

Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of NVP-1203 in Healthy Adult Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02289404

Acronym

NVP-1203

Enrollment

Registered

2014-11-13

Start date

2019-01-18

Completion date

2019-02-28

Last updated

2019-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The purpose of this study is to evaluate food effect on the pharmacokinetics of NVP-1203

Detailed description

This study is designed as randomized, open-label, crossover assignment for evaluate the food effect on the pharmacokinetics of NVP-1203 in healthy adult subjects

Interventions

DRUGNVP-1203

Oral

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* healthy adult subjects who signed informed consent

Exclusion criteria

* Subjects has a history of allergy reaction of study drug ingredient * Subjects participated in another clinical trial within 3 months prior to administration of the study drug * Inadequate subject for the clinical trial by the investigator's decision

Design outcomes

Primary

Measure	Time frame	Description
Pharmacokinetics : Cmax	0-24 hours	Maximum plasma concentration
Pharmacokinetics : AUCt	0-24 hours	Area under the concentration-time curve

Secondary

Measure	Time frame	Description
Pharmacokinetics : AUCinf	0-24 hours	AUC extrapolated to infinity
Pharmacokinetics : Tmax	0-24 hours	Time to reach the Cmax
Pharmacokinetics : t1/2	0-24 hours	Terminal elimination half-life

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026